|
⚠️ Professional Use Only This content is intended exclusively for licensed medical professionals. It does not constitute clinical advice. Always follow applicable regulations and guidelines in your jurisdiction. |
|
✍️ Written by: Celmade Editorial Team | AI-Assisted Content 🔬 Medically Reviewed by: Stella Williams, Medical Aesthetic Injector 📅 Published: April 3rd, 2026 | Last Reviewed: April 3rd, 2026 🔗 View Reviewer Full Profile → celmade.co/pages/team-stella-williams |
|
📌 Editorial Note: This article was drafted with AI assistance and reviewed, fact-checked, and approved by Stella Williams, a qualified Medical Aesthetic Injector. All clinical claims are supported by cited references. |
The botulinum toxin market has expanded significantly over the past decade. Where UK and European practitioners once had a limited choice of two or three products, today's market offers a growing range of formulations from manufacturers in South Korea, Germany, France, and the United States — each with different protein loads, unit strengths, onset profiles, and price points.
For clinic owners and aesthetic practitioners, this creates both opportunity and confusion. Choosing the wrong product — or using the right product with the wrong assumptions about dosing — has direct consequences for patient outcomes and clinic economics. This guide cuts through the marketing and gives you a factual, evidence-based comparison of the four most widely used botulinum toxin Type A products in UK and European aesthetic practice: Botulax, Nabota, Bocouture, and Dysport.
Before diving into the comparison, ensure you are familiar with the fundamentals. Our Complete Guide to Botulinum Toxin Type A covers mechanism of action, reconstitution, dosing principles, contraindications, and the UK regulatory framework for toxin use.
Why Brand Choice Matters More Than Most Practitioners Realise
A common assumption in aesthetic practice is that all botulinum toxin Type A products are fundamentally equivalent — that you can switch freely between brands at the same unit dose with predictable outcomes. This assumption is incorrect, and acting on it leads to either undertreated patients (if you are switching from a potent product to a less potent one at 1:1 dose) or overtreated ones (the reverse).
The reasons for these differences are rooted in manufacturing:
• Bacterial strain: Not all manufacturers use the same strain of Clostridium botulinum. Different strains produce toxin with subtly different potency characteristics, which is why unit equivalence ratios are approximations, not exact conversions.
• Protein complex: Commercial botulinum toxin products consist of the 150 kDa core neurotoxin plus (in most formulations) haemagglutinin and non-haemagglutinin complexing proteins. The total molecular weight of the complex varies between products (300 kDa to 900 kDa), and one product — Bocouture/Xeomin — contains the core toxin only, with no complexing proteins. This affects immunogenicity risk over time.
• Biological activity per vial: Units are not a weight measurement. They are a biological activity measurement based on the LD50 in a specific mouse assay — and different manufacturers use slightly different assay conditions. This means 100 units of Product A and 100 units of Product B may produce different levels of muscle paralysis even if both are correctly dosed by their respective manufacturer's standards.
This is why the British Journal of Dermatology's comparative potency studies consistently emphasise that unit conversion ratios should be treated as clinical guidance, not pharmacological equivalence. Knowing the product you are using — its formulation, its clinical behaviour, and its evidence base — is a core component of safe practice.
Side-by-Side Comparison: Key Product Properties
|
Property |
Botulax |
Nabota |
Bocouture (Xeomin) |
Dysport |
|
Manufacturer |
Hugel (South Korea) |
Daewoong (South Korea) |
Merz (Germany) |
Ipsen (France/UK) |
|
Generic name |
Letibotulinumtoxin A |
Prabotulinumtoxin A |
Incobotulinumtoxin A |
Abobotulinumtoxin A |
|
Bacterial strain |
CBFC26 strain, Type A |
ATCC 3502 strain, Type A |
Hall strain, Type A |
Type A (Hall-derived) |
|
Complexing proteins |
Yes — full complex |
Yes — full complex |
No — core toxin only ('naked') |
Yes — full complex |
|
Protein load (approx.) |
< 5 ng per 100U vial |
< 5 ng per 100U vial |
0.44 ng per 100U vial |
4.35 ng per 500U vial |
|
Available vial sizes |
50U, 100U, 200U |
50U, 100U, 200U |
50U, 100U, 200U |
300U, 500U |
|
Standard unit equiv. to Botox 1U |
~1 : 1 (most studies) |
~1 : 1 (most studies) |
1 : 1 (confirmed) |
~2.5–3 : 1 |
|
Onset (aesthetic use) |
3–5 days |
3–5 days |
3–5 days |
2–5 days |
|
Peak effect |
2 weeks |
2 weeks |
2 weeks |
2–4 weeks |
|
Duration (avg.) |
3–4 months |
3–4 months |
3–4 months |
3–4 months |
|
Spread profile |
Similar to Botox |
Similar to Botox |
Comparable to Botox; some reports of slightly less spread |
Greater spread — relevant for large muscle groups |
|
Cold chain storage |
2–8°C (refrigerated) |
2–8°C (refrigerated) |
Room temp (up to 25°C) before reconstitution |
2–8°C (refrigerated) |
|
CE marked / MFDS approved |
CE marked + MFDS approved |
CE marked + MFDS approved |
CE marked + FDA approved |
CE marked + FDA approved |
|
Relative cost (est.) |
Lower — significant saving vs Botox |
Lower — comparable to Botulax |
Mid-range — premium to Korean brands |
Mid-range — larger vial format |
|
Note on Botox / onabotulinumtoxinA: Botox (Allergan/AbbVie) is the market reference product and the standard against which other products are compared. It is not included in this comparison table as it is not part of the Celmade product range. Where unit equivalence ratios are given for other products above, '1U Botox' is the reference point. For a full product listing including Botulax and Nabota, see our botulinum toxin collection. |
Brand-by-Brand Clinical Analysis
|
Botulax (letibotulinumtoxinA) — Hugel, South Korea The Korean market leader. CE marked, MFDS approved, and the most clinically studied Korean toxin. |
|
✓ Strengths • Extensive real-world clinical data in both Asian and European patient populations • 1:1 unit equivalence with Botox confirmed across multiple peer-reviewed studies — straightforward to adopt • CBFC26 strain has been associated with a clean, consistent onset profile in clinical use • Available in 50U, 100U, and 200U vials — flexible for different clinic volumes • Significantly lower cost per unit than Allergan Botox or European alternatives — substantial margin improvement for busy clinics • CE marked for use in the UK and EU market; MFDS approved in Korea • Strong cold chain documentation and track record across European distribution ✗ Considerations • Contains complexing proteins — relevant if switching patients who have previously had reactions to protein-containing formulations • Refrigerated storage required (2–8°C) — less convenient than Bocouture for clinics without continuous cold chain • Some practitioners report slightly faster dissipation in high-movement areas vs Bocouture, though evidence for this is largely anecdotal Best for: Clinics seeking high-volume cost efficiency without compromising on quality or clinical evidence. Straightforward conversion from Botox with no dose adjustment required in most patients. |
|
Nabota (prabotulinumtoxinA) — Daewoong, South Korea FDA and CE approved. The first Korean botulinum toxin to receive full US FDA approval. |
|
✓ Strengths • The only Korean botulinum toxin Type A product with full FDA approval for aesthetic use (under the brand name Jeuveau in the USA) — a significant regulatory milestone that supports clinical confidence • CE marked for European use; MFDS approved in Korea • 1:1 unit equivalence with Botox — same conversion simplicity as Botulax • Available in 50U, 100U, and 200U vials • Comparable onset and duration profile to Botulax and Botox in clinical practice • Competitive pricing — similar to Botulax, representing strong value vs European alternatives • Multiple peer-reviewed studies supporting efficacy and safety in aesthetic applications ✗ Considerations • Contains complexing proteins — same immunogenicity consideration as Botulax • Refrigerated storage required • Less widely known by name among UK patients than European brands, though this has no clinical relevance Best for: Clinics that want Korean product economics combined with the reassurance of FDA approval as an additional evidence marker — particularly useful when discussing product credibility with well-informed patients. |
|
Bocouture (incobotulinumtoxinA) — Merz, Germany The only 'naked' toxin — zero complexing proteins. Best choice for patients with previous non-response or high immunogenicity risk. |
|
✓ Strengths • Zero complexing proteins — the lowest immunogenicity risk of any currently available botulinum toxin Type A product • Room temperature stable before reconstitution (up to 25°C) — genuine logistical advantage for clinics with storage constraints or for mobile practitioners • 1:1 unit equivalence with Botox — confirmed by multiple clinical trials • CE marked and FDA approved • Clinically established track record with extensive European peer-reviewed literature • Excellent choice for patients who report declining duration or reduced response to protein-containing products ✗ Considerations • Higher cost per unit than Korean alternatives — smaller margin improvement compared to Botulax or Nabota • Some practitioners report a perception of slightly less spread, which is advantageous in precision zones but may require slight technique adjustment for large-area treatments • Not CE marked for all indications in every European country — verify local product approval for specific indications (e.g. hyperhidrosis) Best for: Patients with previous botulinum toxin non-response, suspected antibody formation, or a history of allergic reactions. High-frequency treatment patients (every 3 months over several years) where protein-induced immunogenicity is a long-term concern. Mobile practitioners who cannot guarantee continuous cold chain. |
|
Dysport (abobotulinumtoxinA) — Ipsen, UK/France The European alternative with greater spread. Units work differently — critical to convert correctly. |
|
✓ Strengths • Longer-established European regulatory history — CE marked and FDA approved for multiple aesthetic and medical indications • Greater spread profile than Botox-equivalent products — an advantage for large muscle group treatments (masseter, frontalis, platysma, hyperhidrosis) • Available in large-format vials (300U, 500U) — cost-efficient for high-volume clinics treating large areas • Faster onset reported in some studies — may begin to show effect within 24–48 hours in some patients • Well-documented for non-cosmetic indications including spasticity and hyperhidrosis ✗ Considerations • Unit conversion is NOT 1:1 with Botox or Korean products — 1U Botox ≈ 2.5–3U Dysport. Dosing errors from incorrect conversion are the most common cause of over-treatment complications with Dysport • Greater spread is a disadvantage in precision zones (lips, crow's feet, periorbital) where unintended diffusion causes complications • Protein load is higher than Korean alternatives at the equivalent therapeutic dose • Larger vial formats require higher per-session volumes to be cost-efficient — less flexible for low-volume clinics Best for: High-volume treatments where greater spread is therapeutically beneficial: hyperhidrosis, masseter reduction, platysma, frontalis (experienced injectors only). Not recommended as a first-line switch for clinics accustomed to Botox-unit products without clear training on the unit conversion. |
Unit Conversion: The Most Important Clinical Detail
The single most dangerous assumption a practitioner can make when switching botulinum toxin brands is that units are equivalent. For three of the four products in this comparison — Botulax, Nabota, and Bocouture — the 1:1 conversion from Botox-standard units applies and switching is relatively straightforward. Dysport is the critical exception.
|
If your standard Botox dose is... |
Use this dose of Botulax |
Use this dose of Nabota |
Use this dose of Bocouture |
Use this dose of Dysport |
|
Glabella: 20U |
20U |
20U |
20U |
50–60U |
|
Glabella: 25U |
25U |
25U |
25U |
62–75U |
|
Forehead: 10U |
10U |
10U |
10U |
25–30U |
|
Crow's feet: 12U/side |
12U/side |
12U/side |
12U/side |
30–36U/side |
|
Masseter: 30U/side |
30U/side |
30U/side |
30U/side |
75–90U/side |
|
Lip flip: 4U |
4U |
4U |
4U |
10–12U |
|
Critical: Dysport conversion The conversion ratio for Dysport ranges from 2.5:1 to 3:1 (Dysport units : Botox-equivalent units) depending on the anatomical area and study cited. Use 2.5:1 as your conservative starting point for new patients and adjust based on 2-week review. The table above uses a 2.5:1 ratio. Never assume 1:1 when switching to or from Dysport. For a complete conversion reference with notes on area-specific adjustment, see our dedicated Botulinum Toxin Unit Conversion Guide. |
Protein Load and Immunogenicity: The Long-Term Consideration
For most patients receiving two to four treatments per year at standard aesthetic doses, the protein load of the toxin formulation they receive has minimal short-term clinical relevance. However, for a significant subset of patients — those treated frequently, at high doses, or over many years — the cumulative exposure to non-toxin complexing proteins is associated with a higher risk of neutralising antibody formation.
Neutralising antibodies bind to the botulinum toxin molecule and prevent it from acting at the neuromuscular junction. Clinically, this manifests as a gradual reduction in duration of effect, followed by a reduction in degree of effect, eventually resulting in complete non-response. This is a real and documented phenomenon — estimated to affect approximately 1–3% of long-term aesthetic toxin patients in some studies.
|
Product |
Complexing Proteins |
Total Protein Load |
Relative Immunogenicity Risk |
|
Bocouture (Xeomin) |
None — core toxin only |
0.44 ng per 100U vial |
Lowest — the only protein-free formulation |
|
Botulax |
Yes — full complex |
< 5 ng per 100U vial |
Low — comparable to Botox |
|
Nabota |
Yes — full complex |
< 5 ng per 100U vial |
Low — comparable to Botox |
|
Dysport |
Yes — full complex |
4.35 ng per 500U vial (higher effective dose needed) |
Moderate — higher protein exposure at equivalent therapeutic effect |
For patients who report declining effect, the clinical approach is to: (1) rule out technical causes (inadequate dose, incorrect targeting, cold chain failure); (2) consider switching to Bocouture to reduce ongoing protein exposure; (3) extend the inter-treatment interval to allow any antibody response to wane. For a full guide to managing this issue, see our post on botulinum toxin resistance and antibody formation.
Cold Chain and Storage: A Practical Clinic Consideration
Cold chain compliance is one of the most overlooked quality factors in botulinum toxin use. Every product's potency is time-temperature sensitive — exposure to temperatures outside the recommended range degrades the protein structure and reduces biological activity, leading to inconsistent clinical results even at correct doses.
|
Product |
Storage Before Reconstitution |
After Reconstitution |
Special Note |
|
Botulax |
2–8°C (refrigerated) |
Use within 4–24 hours at 2–8°C |
Do not freeze reconstituted product |
|
Nabota |
2–8°C (refrigerated) |
Use within 4 hours (manufacturer guidance) |
Can be stored frozen before reconstitution per SPC — verify per batch |
|
Bocouture |
Up to 25°C (room temperature) |
Use within 24 hours at 2–8°C |
Room-temp stability before reconstitution is a genuine clinical advantage for mobile practitioners |
|
Dysport |
2–8°C (refrigerated) |
Use within 4–8 hours at 2–8°C |
Large vial format — plan patient volume to avoid waste once reconstituted |
For a full clinic compliance guide covering storage requirements, documentation obligations, and what to check when receiving a delivery, see our post on cold chain and storage for botulinum toxin.
Cost per Unit and Clinic Economics
Botulinum toxin is one of the highest-volume consumables in most aesthetic clinics. A seemingly small difference in cost per unit, multiplied across hundreds of treatments per year, produces a significant difference in clinic economics. The following is a generalised cost comparison framework — actual prices vary by supplier, volume commitment, and market conditions.
|
Product |
Relative Cost (vs Botox 100U) |
Estimated Saving per 100U |
Margin Impact at 10 Treatments/Week |
|
Botox 100U |
Reference (100%) |
— |
Reference |
|
Botulax 100U |
~40–55% of Botox cost |
Significant — est. £40–80+ per vial saving |
£400–800+ additional margin per week at standard pricing |
|
Nabota 100U |
~40–55% of Botox cost |
Comparable to Botulax |
Similar to Botulax margin improvement |
|
Bocouture 100U |
~65–80% of Botox cost |
Moderate — est. £15–35 per vial saving |
Meaningful at volume but less than Korean alternatives |
|
Dysport 500U |
Requires dose conversion — cost per effective unit is competitive at high volumes |
Depends heavily on patient volume and treatment area |
Best economics at high volumes where spread profile is an advantage |
|
Clinic economics note: Switching from Botox to Botulax or Nabota at 1:1 dosing, while maintaining your current patient pricing, can add substantial annual margin to a busy aesthetic clinic without any change in patient outcomes. Many practitioners make this switch and report no difference in patient satisfaction or treatment duration. The key is a structured transition: inform your team, brief your key patients, and document the switch in every patient record. |
So Which Product Should Your Clinic Stock?
The honest answer is that most established clinics benefit from stocking more than one product. Each has a specific use case where it performs best:
|
Clinical Situation |
Recommended Product |
Reason |
|
Standard aesthetic treatments — new patients, standard muscle mass |
Botulax or Nabota |
1:1 conversion, proven efficacy, lowest cost, CE marked. Straightforward adoption. |
|
Patient with declining response to previous toxin |
Bocouture (Xeomin) |
Zero protein load — lowest immunogenicity. Appropriate for suspected antibody formation. |
|
Mobile practitioner or satellite clinic without dedicated refrigerator |
Bocouture (Xeomin) |
Room temperature stable before reconstitution — only option suitable for non-refrigerated storage |
|
Large-area treatments: hyperhidrosis, masseter, platysma |
Dysport or high-dose Botulax |
Dysport's greater spread reduces injection points for large areas. Botulax at higher concentration is an alternative. |
|
Patient requesting 'European brand' for personal preference |
Bocouture (Merz, Germany) |
German-manufactured, CE and FDA approved — addresses patient concern without compromising margins as severely as Botox. |
|
High-volume clinic, price-sensitive market |
Botulax or Nabota (primary), Bocouture (secondary) |
Korean products as primary stock for margin; Bocouture for specialist cases. |
Frequently Asked Questions
Is Botulax as good as Botox?
Yes — the clinical evidence supports equivalent outcomes between Botulax and Botox at 1:1 dosing for standard facial aesthetic applications. Multiple peer-reviewed studies, including Moers-Carpi et al. (2012) in the Journal of Drugs in Dermatology and real-world practitioner data across European markets, demonstrate non-inferiority of Botulax to the Botox reference product. The differences in patient outcomes reported by practitioners are almost always attributable to technique, reconstitution, or dosing — not inherent product inferiority.
Do I need to tell my patients if I switch botulinum toxin brands?
In the UK, practitioners are required to provide patients with sufficient information to give informed consent to treatment, which includes information about the products being used. If you switch from a product a patient has previously had (e.g. from Botox to Botulax), good practice — and arguably good clinical governance — is to inform the patient of the change and document this in the record. It does not need to be presented as a downgrade; frame it accurately as a CE-marked product with equivalent clinical evidence at a unit dose that remains the same.
Can I mix different brands in the same treatment session?
Technically, different products can be used in the same session (for example, Bocouture for the glabella due to immunogenicity concerns, and Botulax for the masseter). However, this significantly increases the complexity of patient records, requires very clear documentation of which product was used where, and makes attribution of any adverse events more complicated. Most practitioners who use multiple products do so to specialise each product for specific patient profiles rather than mixing within a single session.
Is Nabota FDA approved?
Yes. Nabota (prabotulinumtoxinA) received FDA approval in 2019 for the treatment of glabellar lines in adults, marketed in the USA under the brand name Jeuveau by Evolus. This makes it the only Korean botulinum toxin Type A product with full US FDA approval for aesthetic use — in addition to its CE marking for the UK and European market.
How do I know if my botulinum toxin is cold chain compliant when it arrives?
All reputable suppliers should provide temperature monitoring documentation with each delivery — this may be a data logger printout, a time-temperature indicator (TTI) label on the outer packaging, or a written declaration from the logistics partner. On receipt, check the product packaging for intact seals, inspect vials for particulates or unusual colouration after reconstitution, and verify the batch number against the delivery documentation. If any doubt exists about cold chain integrity, do not use the product. For a full receipt and storage checklist, see our guide on cold chain compliance for botulinum toxin.
Making Your Choice: A Framework for Brand Selection
Choosing a botulinum toxin product for your clinic is a clinical and commercial decision that deserves the same rigour you would apply to any other aspect of patient care. The good news is that the evidence base is clear: Botulax and Nabota offer genuine clinical equivalence to Botox at a fraction of the cost, CE marking confirms their compliance for UK and EU use, and their 1:1 unit equivalence makes adoption straightforward.
Bocouture earns its place in any well-stocked clinic's product range as the go-to choice for patients with immunogenicity concerns or for practitioners who need room-temperature storage. Dysport remains the product of choice for practitioners who routinely treat large muscle groups and are comfortable with the unit conversion.
Browse Celmade's full botulinum toxin range including Botulax and Nabota across all vial sizes, or continue building your clinical knowledge with our related guides: botulinum toxin unit conversion between brands, upper face dosing reference, and managing botulinum toxin resistance.
